Clinically Relevant Benefits Seen for GLP-1RA, SGLTi Treatment of T1DM

THURSDAY, March 2, 2023 -- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are beneficial for treating type 1 diabetes mellitus (T1DM), with similar reductions in glycated hemoglobin A1c...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news